JNJ-87890387

Unknown / undisclosed

Also known as JNJ-0387

Phase 1Mechanism not established

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Advanced Solid Tumors
NCT06178614 · Janssen Research & Development, LLC
2023-12-14 – 2029-02-07 · Neoplasms, Advanced Solid Tumors
What this study did

Competitive landscape

This drug's own stage for Advanced Solid Tumors: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
JNJ-87890387: this drugPhase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
AZD4956
Phase 1/2(overall)
Small moleculePOLQ (DNA polymerase theta)not yet gradedNo reviewed efficacy summary in this indication
BMS-986517Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
BMS-986548
Phase 1/2(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
HRS-6768Phase 1/2UndisclosedFibroblast Activation Protein (FAP)not yet gradedNo reviewed efficacy summary in this indication
HRS-8364Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
Palacaparib
Phase 1/2(overall)
Small moleculePARP1 inhibitor (next-gen)not yet gradedNo reviewed efficacy summary in this indication
REGN10597Phase 1/2Multispecific antibodyPD-1 x IL-2Rα (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
SHR-1681Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-4298
Phase 1/2(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-4375Phase 1/2Antibody–drug conjugateTissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF)not yet gradedNo reviewed efficacy summary in this indication
SHR-4610Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-7787Phase 1/2Multispecific antibodyDLL3 (Delta-like ligand 3) x CD3not yet gradedNo reviewed efficacy summary in this indication
SHR-9803Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
TAK-188
Phase 1/2(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
TAK-505
Phase 1/2(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
ABBV-253Phase 1Biologic (subtype unspecified)c-METnot yet gradedNo reviewed efficacy summary in this indication
BMS-986500Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
GSK5533524Phase 1Antibody–drug conjugateMUC16not yet gradedNo reviewed efficacy summary in this indication
HRS-6093Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
JNJ-89862175Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
MP0310Phase 1Protein / enzyme therapeuticFAP x 4-1BB (CD137)not yet gradedNo reviewed efficacy summary in this indication
SHR-3821Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-4685
Phase 1(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-4849Phase 1Antibody–drug conjugateDLL3not yet gradedNo reviewed efficacy summary in this indication
SHR-7782
Phase 1(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
TAK-168
Phase 1(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
YS-ON-001Phase 1Biologic (subtype unspecified)TLR3 (poly I:C adjuvant)not yet gradedNo reviewed efficacy summary in this indication
225Ac-ETN029
—(overall)
Radioligand Therapy (actinium-225)DLL3not yet gradedNo reviewed efficacy summary in this indication
AAA614
—(overall)
Radioligand TherapyFibroblast Activation Protein (FAP)not yet gradedNo reviewed efficacy summary in this indication
AZD5863
—(overall)
Multispecific antibodyClaudin 18.2 x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD9793
—(overall)
Multispecific antibodyGlypican-3 (GPC3) x CD3not yet gradedNo reviewed efficacy summary in this indication
BMS-986506
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
GCJ904
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
GSK5460025
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
PF-08032560
—(overall)
Small moleculeKAT6A/KAT6B and KAT7not yet gradedNo reviewed efficacy summary in this indication
PF-08046044
—(overall)
Antibody–drug conjugateAnti-CD30 antibody-drug conjugatenot yet gradedNo reviewed efficacy summary in this indication
RG6505
—(overall)
UndisclosedRAS (pan-RAS, RAS-mutant tumors)not yet gradedNo reviewed efficacy summary in this indication
RG6620
—(overall)
UndisclosedKRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
RG6648
—(overall)
Antibody–drug conjugatec-METnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow JNJ-87890387 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
March 2027 (1)
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2027-03-16 · NCT06178614 · CT.gov ↗
What to watch

See the full readout calendar ↗